AIC
SABS icon

AWM Investment Company’s SAB Biotherapeutics SABS Stock Holding History

AWM Investment Company’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
375,000
-25,000
-6% -$93K 0.13% 89
2026
Q1 		$1.53M Buy
400,000
+200,000
+100% +$797K 0.17% 81
2025
Q4 		$748K Hold
200,000
– – 0.07% 98
2025
Q3 		$402K Buy
+200,000
New +$452K 0.04% 102

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AWM Investment Company's SABS Position: Q2 2026 in Review

AWM Investment Company reduced its SAB Biotherapeutics (SABS) stake by 6.3% in Q2 2026, selling an estimated $93K and leaving 375,000 shares worth $1.46M. The position accounts for 0.13% of the portfolio, ranked #89.

AWM Investment Company first reported a position in SABS in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.53M in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • AWM Investment Company held 375,000 shares of SAB Biotherapeutics worth $1.46M as of Q2 2026.
  • AWM Investment Company sold 25,000 SAB Biotherapeutics shares in Q2 2026, an estimated $93K.
  • SAB Biotherapeutics made up 0.13% of AWM Investment Company's portfolio in Q2 2026, its #89 holding.
  • AWM Investment Company first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • AWM Investment Company's SAB Biotherapeutics position peaked at $1.53M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on AWM Investment Company's 13F filing for Q2 2026, filed 14 Aug 2026.